Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sadhvi Khanna"'
Autor:
Panagiotis Panagiotidis, K Govind Babu, Sadhvi Khanna, Andrew R. Pettitt, Sebastian Grosicki, Olena Werner, Ghislaine Vincent, Jiri Mayer, Marco Montillo, Fritz Offner, Tadeusz Robak, Peter Hillmen, Anna Schuh, Ann Janssens, Janusz Kloczko
Publikováno v:
BRITISH JOURNAL OF HAEMATOLOGY
The Complement 1 trial investigated the efficacy and safety of ofatumumab + chlorambucil with chlorambucil monotherapy in patients with previously untreated chronic lymphocytic leukaemia (CLL). On long-term follow-up in the chemoimmunotherapy arm vs.
Autor:
Yi-Long Wu, Ji-Youn Han, Terufumi Kato, Fabrice Barlesi, Edward B. Garon, Federico Cappuzzo, Yuji Shibata, Nathalie Smith, Sadhvi Khanna, Riccardo Belli, Alejandro Yovine, Daniel Tan
Publikováno v:
Cancer Research. 82:CT559-CT559
Background: MET amplification can arise as a bypass resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs) and occurs in ~5-26% of EGFR TKI resistant EGFR-mutant non-small cell lung cancer (NSCLC). These patients (pts) have limited treatment
Autor:
Yi-Long Wu, Ji-Youn Han, Terufumi Kato, Fabrice Barlesi, Edward B. Garon, Federico Cappuzzo, Yuji Shibata, Nathalie Smith, Sadhvi Khanna, Riccardo Belli, Alejandro Javier Yovine, Daniel S.W. Tan
Publikováno v:
Journal of Clinical Oncology. 40:TPS9153-TPS9153
TPS9153 Background: MET amplification can arise as a bypass resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs) and occurs in ̃5-26% of EGFR TKI resistant EGFR-mutant non-small cell lung cancer (NSCLC). These patients (pts) have limited t
Autor:
Ghislaine Vincent, Sebastian Grosicki, Ann Janssens, Andrew R. Pettitt, Fritz Offner, Janusz Kloczko, Peter Hillmen, Sadhvi Khanna, Govind Babu Kanakasetty, Tadeusz Robak, Anna Schuh, Panagiotis Panagiotidis, Jiri Mayer, Olena Werner, Marco Montillo
Publikováno v:
Journal of Clinical Oncology. 37:7528-7528
7528 Background: Previously in the COMPLEMENT 1 study, treatment with OFA and CHL in pts with untreated CLL had shown a significant improvement in the progression-free survival (PFS) compared with CHL alone, and was well tolerated. Here, we report th
Autor:
Carmen Garcia-Hernandez, Sadhvi Khanna, Andrey Zaritskey, Haifa Kathrin Al-Ali, Renato Tavares, Bruno Martino, Vikas Gupta, Alessandro M. Vannucchi, Philipp le Coutre, Pia Raanani, Catherine Bouard, Martin Griesshammer, Giuseppe A. Palumbo, Pilar Giraldo, Anna Marina Liberati, Lynda Foltz, Julian Perez Ronco, Francesca Palandri
BACKGROUND: Ruxolitinib is a potent JAK1/JAK2 inhibitor that has proved superior to placebo and best available therapy in the phase 3 COMFORT studies for patients (pts) with intermediate (Int)-2- or high-risk myelofibrosis (MF). Ruxolitinib-treated p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d917c18d502e82feeaf0418cf3875d12
http://hdl.handle.net/11391/1406572
http://hdl.handle.net/11391/1406572
Autor:
José Salvador Rodrigues de Oliveira, Philipp le Coutre, Zhi Xiang Shen, Israel Bendit, Xiaojun Huang, Sadhvi Khanna, Kudrat Abdulkadyrov, Sandip Shah, Eduardo Bullorsky, Manuel Ayala, Rafik Fellague-Chebra, Tina Owugah, Carmino Antonio De Souza, Tomasz Szczudlo, Zhizhou Liang, Jose Luis Lopez, Jorge E. Cortes, Tomasz Sacha, K Govind Babu
Summary Background Optimal management of patients with chronic myeloid leukaemia in chronic phase with suboptimal cytogenetic response remains undetermined. This study aimed to investigate the safety and efficacy of switching to nilotinib vs imatinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68078b339f1dc0219f0e967d94164e2d
https://ruj.uj.edu.pl/xmlui/handle/item/94510
https://ruj.uj.edu.pl/xmlui/handle/item/94510
Autor:
Kudrat Abdulkadyrov, Hang Quach, Sadhvi Khanna, Timothy P. Hughes, Jeffrey H. Lipton, Anna G. Turkina, Luis Meillon, Marco Aurelio Salvino, Vernon J. Louw, Alaa Elhaddad, Jake Shortt, Darshan Dalal, Carolina Pavlovsky, Yu Jin, Lee-Yung Shih, Ong Tee Chuan
Publikováno v:
Blood. 126:344-344
Background: In the pivotal Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, frontline NIL 300 mg and 400 mg twice daily (BID) resulted in higher rates of deep molecular response and lower rates of